Search results
Analysis-Stelara patent deal puts J&J back on path to $57 billion 2025 revenue forecast
Reuters via Yahoo Finance· 11 months agoJohnson & Johnson's legal settlement with Amgen Inc to delay a biosimilar version of its blockbuster...
From Nurse To Patient: My Journey With Crohn’s Disease
Women's Health via Yahoo News· 2 years agoAs a healthcare professional, Alison spent her days doing endoscopies, which are one of the many...
J&J's medical device sales fall short, cancer drugs seen growing
Reuters via Yahoo Finance· 4 weeks ago(Reuters) -Johnson & Johnson's first-quarter revenue missed Wall Street estimates for medical...
J&J sues Amgen over plan to sell drug similar to blockbuster Stelara
Reuters via Yahoo Finance· 1 year ago(Reuters) -Johnson & Johnson's Janssen unit has sued Amgen Inc over its plan to market a drug for...
Unexpected drugs make first round of Medicare negotiations
The Hill via Yahoo News· 8 months agoThe Centers for Medicare and Medicaid Services (CMS) have officially named the first 10 drugs chosen...
Johnson & Johnson Stock Is Great. Here's Why You Shouldn't Buy It.
Motley Fool via Yahoo Finance· 2 months agoJohnson & Johnson (NYSE: JNJ) is one of the leading and most recognizable names in healthcare. It...
Novartis' Sandoz targets biosimilar version of J&J drug in Samsung deal
Reuters via Yahoo News· 8 months agoFRANKFURT (Reuters) -Novartis' generic-drugs unit Sandoz said on Monday it plans to launch a generic...
What to know about the Biden administration’s Medicare drug price negotiations
Miami Herald via Yahoo News· 7 months agoThe Biden administration announced in August that 10 costly prescription drugs have been selected...
U.S. drug price negotiations are underway. Here’s what that will mean for you—eventually
Fortune via Yahoo Finance· 3 months agoNegotiations are underway between the federal government and pharmaceutical companies to determine...
Pharma CEOs, pressed by Senate panel, refuse to commit to price cuts
BioPharma Dive via Yahoo Finance· 3 months agoThe CEOs of three major drugmakers defended the prices they charge U.S. patients in a Senate...